Cargando…
Comparison of the risk of heart failure in psoriasis patients using anti‐TNF α inhibitors and ustekinumab
Autores principales: | Han, Ju Hee, Park, Hae Eun, Kim, Yeong Ho, Jung, Jin‐Hyung, Lee, Ji Hyun, Park, Young Min, Bang, Chul Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934959/ https://www.ncbi.nlm.nih.gov/pubmed/35174665 http://dx.doi.org/10.1002/ehf2.13855 |
Ejemplares similares
-
Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
por: Kim, Ye Seul, et al.
Publicado: (2016) -
Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011) -
Changes in metabolic syndrome and risk of psoriasis: a nationwide population-based study
por: Lee, Hyun Ji, et al.
Publicado: (2021) -
Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020) -
Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)